Compare BSTZ & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSTZ | VCEL |
|---|---|---|
| Founded | 2019 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | BSTZ | VCEL |
|---|---|---|
| Price | $25.44 | $33.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 172.5K | ★ 644.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.71 | 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ $35.79 | $111.97 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $17.00 | $28.95 |
| 52 Week High | $25.47 | $45.97 |
| Indicator | BSTZ | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 76.43 | 48.78 |
| Support Level | $20.66 | $31.24 |
| Resistance Level | N/A | $34.77 |
| Average True Range (ATR) | 0.46 | 1.46 |
| MACD | 0.29 | 0.24 |
| Stochastic Oscillator | 97.62 | 49.86 |
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.